The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball, Susan; Vickery, J; Hobart, J; et al.Wright, D; Green, C; Shearer, J; Nunn, A; Gomez Cano, M; MacManus, D; Miller, D; Mallik, S; Zajicek, J
Date: 1 February 2015
Journal
Health Technology Assessment
Publisher
NIHR Health Technology Assessment Programme
Publisher DOI
Related links
Abstract
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ(9)-tetrahydrocannabinol (Δ(9)-THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid administration; and, improve methods for testing treatments in progressive MS.
Institute of Health Research
Collections of Former Colleges
Item views 0
Full item downloads 0